Stocks

Investors should prioritize Oscar Health (OSCR) as a high-conviction mid-term trade, as it currently trades at a massive valuation discount with projected 61% revenue growth. The Real Brokerage (REAX) offers a prime opportunity to play a future interest rate pivot, maintaining 51% growth despite macro headwinds and trading well below its historical value. In the fintech sector, NuBank (NU) is a top-tier growth pick as it expands into the U.S. market, while Webull (WEBLL) represents a significant value play compared to the more expensive Robinhood (HOOD). For those seeking healthcare exposure, Hims & Hers (HIMS) remains undervalued relative to its profitability and transparent pricing model even after its recent rally. Focus on companies with an EV/GP/RG metric under 0.5, as many high-growth disruptors in Fintech and Telehealth are currently being ignored by the broader market.

Investors can capitalize on the viral NeeDoh toy trend by purchasing Gladstone Investment Corporation (GAIN), a small-cap BDC that owns the brand's parent company and offers a high 7% dividend. Monitor GAIN’s upcoming May earnings for revenue spikes, but avoid chasing price jumps due to the stock's low liquidity. Amazon (AMZN) remains a high-conviction long-term play for AI infrastructure; any price dips below $185-$200 caused by rising oil prices should be viewed as a prime buying opportunity. For a "picks and shovels" play on AI data center energy needs, Bloom Energy (BE) is currently attractive following a market overreaction to project rumors. Finally, prioritize liquid, best-in-class public AI stocks like NVIDIA and Microsoft over private equity deals to avoid high fees and lock-up periods.

High-conviction "super investors" are currently capitalizing on a massive 26% year-to-date drawdown in FICO, viewing the current price as a rare entry point for a company that remains the essential "common language" of credit. Uber (UBER) is trading at a historically cheap 22x forward P/E, offering a 5-6% free cash flow yield for investors who believe its massive network effect can successfully integrate autonomous vehicle technology. Intuit (INTU) and S&P Global (SPGI) have both fallen significantly due to AI disruption fears, yet they currently trade at multi-year valuation lows despite maintaining dominant, near-monopoly market positions. Microsoft (MSFT) has shifted from overvalued to undervalued at a 23x forward P/E, providing a high-margin opportunity for those willing to look past short-term AI infrastructure spending. For those seeking a diversified compounder, Brookfield Corporation (BN) is currently discounted by 15% due to macro interest rate fears rather than business fundamentals, making it a top pick for long-term value seekers.

Oracle (ORCL) is a high-conviction growth play following a "quadruple beat" in earnings, with a technical price target of $178–$180 if it maintains momentum above its 50-day moving average. NVIDIA (NVDA) remains a top large-cap pick leading into the GTC Conference on March 17th, though investors should watch for a "sell the news" event if the stock hits resistance at $195. For the software sector, look to accumulate Microsoft (MSFT) near support levels of $392–$395 and Salesforce (CRM) at $195 as these high-quality names begin to bottom out. In the energy space, Crude Oil and the USO ETF offer a "catch-up" trade opportunity as long as prices hold above $75 and $92 respectively amid geopolitical tensions. Given that interest rate cuts may be delayed until September, investors should consider using covered calls on existing positions to generate income during this period of market volatility.

Investors should consider Hims & Hers Health (HIMS) as a high-conviction growth play, with a price target of $30 driven by strong recurring revenue and a low valuation of 1.7x forward revenue. MicroStrategy (MSTR) remains a top pick for Bitcoin exposure, as the company aggressively uses equity offerings to increase its total crypto holdings per share. For short-term traders, the MSTR "Stretch" instrument offers a high-liquidity opportunity to capitalize on heavy volume near the $100 price level. Bitcoin (BTC) is currently acting as a leading indicator for the broader market; watch for the Fear and Greed Index to move into neutral territory as a signal to increase equity exposure. Focus your portfolio on assets with high liquidity and clear capital allocation strategies to navigate the current macro volatility and geopolitical uncertainty.

Investors should maintain a bullish outlook on NVIDIA (NVDA) as it expands into software and AI agents, with the upcoming GTC Conference serving as a major price catalyst. Oracle (ORCL) presents a high-conviction opportunity if earnings guidance confirms the $300 billion OpenAI partnership, potentially driving the stock back toward the $150-$155 range. Hims & Hers Health (HIMS) is a strong momentum play following a Bank of America upgrade to a $24 price target, though investors should expect continued volatility. Conversely, caution is advised for the software sector (IGV, CRM, ADBE) as NVIDIA’s entry into AI agents threatens traditional SaaS business models. In the energy sector, the removal of the "war premium" makes Crude Oil (WTI) and stocks like Exxon (XOM) bearish targets as prices stabilize near $88-$90.

The S&P 500 (SPY) and Nasdaq-100 (QQQ) have signaled a strong bullish reversal following geopolitical de-escalation, with the 670 level on the S&P serving as a critical support floor for new long positions. Investors should consider NVIDIA (NVDA) and Marvell (MRVL) as high-conviction plays, specifically targeting the shift toward "Photonics" and optical interconnects as the next major AI infrastructure bottleneck. Hims & Hers Health (HIMS) remains a high-reward momentum trade with a potential short squeeze target of $30 following the resolution of its legal battle with Novo Nordisk. For those betting on lower energy costs, American Airlines (AAL) offers a direct tactical trade to benefit from the sharp downward reversal in Crude Oil (WTI) prices toward the $85 range. In the software sector, Rubrik (RUBR) presents a compelling valuation play at 7x EV/Sales for investors seeking a discounted entry into AI-driven data security.

Investors should consider buying the dip in Netflix (NFLX), as its low-cost entertainment model is "anti-fragile" and likely to gain market share if high energy prices force consumers to cancel expensive travel. Amazon (AMZN) remains a high-conviction Buy with a target of 20% compounded annual returns, leveraging its dominant retail position and AWS growth to offset rising shipping costs. Accumulate shares of Meta (META) and Microsoft (MSFT) during current market volatility, while maintaining a Hold on Google (GOOGL) due to its elevated valuation. Geopolitical instability in the Strait of Hormuz is a long-term tailwind for ASML, as nations invest in "sovereign chip capacity" to secure domestic semiconductor supply chains. Avoid or reduce exposure to consumer discretionary stocks like Uber (UBER) and Booking Holdings (BKNG), which face immediate pressure from $100/barrel oil prices and reduced consumer spending.

Investors should consider Hims & Hers Health (HIMS) as a high-conviction growth play following its strategic partnership with Novo Nordisk (NVO) to distribute branded Wegovy. This deal effectively de-risks the company by resolving legal disputes and securing a long-term supply of both oral and injectable GLP-1 medications. While the stock recently surged, it remains fundamentally undervalued at current levels near $22.00, with internal metrics suggesting it is "dirt cheap" relative to its 35%–45% projected annual growth. Long-term investors can view any short-term "cool off" or 10% price dip as a strategic entry point into a company evolving into a subscription-based "Netflix of healthcare." This shift toward a platform-based model positions HIMS to significantly outperform conservative analyst revenue targets of $6.5 billion by 2030.

Investors should consider MicroStrategy (MSTR) as a high-beta play on Bitcoin, as the company continues to aggressively use equity offerings to acquire massive amounts of the digital asset. While MSTR trades at a premium to its net asset value, management’s strategy of using "At-The-Market" (ATM) offerings to buy BTC is viewed as accretive for long-term shareholders. For a more resilient alternative, Stretch (STRC) is currently outperforming traditional ETFs like IBIT and maintains strong support above the $100 price floor despite broader market volatility. Bitcoin itself has shown significant macro resilience by recovering quickly from dips below $65,000, signaling a technical uptrend and a shift toward becoming a "risk-off" hedge. Current market sentiment levels suggest Bitcoin and its proxies are undervalued, offering a strategic entry point for those looking to capitalize on geopolitical instability and dollar debasement.

With oil prices spiking above $100/barrel, investors should consider hedging against inflation by holding energy giants like Exxon (XOM) and Chevron (CVX), while avoiding fuel-sensitive sectors like Airlines and Cruise Lines. Hims & Hers (HIMS) presents a high-conviction growth opportunity following the dismissal of major legal risks, though investors should watch for a stable entry point between $22 and $25. In the technology sector, NVIDIA (NVDA) has established a strong support floor at $170, making it a primary target for dip buyers ahead of broader AI infrastructure growth. Defense remains a critical theme, with large-cap contractors like Lockheed Martin (LMT) offering stability, while small-cap drone stocks like Red Cat (RCAT) provide high-risk, high-reward exposure to geopolitical tensions. To navigate current market volatility and "Extreme Fear" levels, consider generating yield through Covered Calls on stable mega-cap names like Meta (META) or Amazon (AMZN).

Investors should monitor MicroStrategy (MSTR) for continued Bitcoin accumulation, paying close attention to the "BTC Rating" metric as a drop below 3.0 could signal a loss in the stock's premium. For those seeking high-yield cash alternatives, the 21Shares Core Ethereum ETF (STRC) offers an 11.5% yield and maintains a stable peg near $100.00, providing a low-volatility income opportunity. Robinhood (HOOD) users can gain a mathematical edge by utilizing the new "early dividend" feature to reinvest capital on the ex-dividend date when share prices are typically lower. In the fintech sector, watch for the launch of X Finance and its rumored 6% yield accounts, which aim to disrupt traditional banking by offering significantly higher returns than standard checking accounts. To maximize returns on high-frequency "penny arbitrage" or yield-bearing assets, investors should prioritize using tax-advantaged accounts like IRAs to avoid complex tax implications.

Investors should consider Palantir Technologies (PLTR) as it evolves into a high-margin defense powerhouse with a projected revenue path toward $40 billion by 2030. The company is securing massive 10-year, $10 billion contract vehicles with the U.S. Army, Air Force, and Navy, providing long-term revenue visibility that traditional analysts may be underestimating. Because PLTR acts as a model-agnostic infrastructure provider, it maintains a competitive moat over AI model creators like Anthropic by allowing the military to swap software providers without disrupting operations. Beyond software, the broader Defense & Aerospace sector is poised for growth as the U.S. defense budget potentially expands to $1.5 trillion, benefiting hardware-software integrators like Lockheed Martin (LMT) and Boeing (BA). For those tracking government efficiency, PLTR is becoming the primary tool for auditing federal spending, making it a "must-own" asset for institutional transparency and anti-fraud initiatives.

Investors should consider Hims & Hers Health (HIMS) as a high-conviction play following reports of a major partnership with Novo Nordisk (NVO) or Eli Lilly (LLY) to provide branded weight loss medications. With short interest at 40% of the float, the stock could see a price jump of 40% to 60% in the immediate term, with analysts viewing the $22.00 to $30.00 range as still fundamentally "cheap." A formal partnership would likely re-accelerate revenue growth from 29% to over 45%, transforming HIMS from a compounded drug provider into a massive distribution platform for "Big Pharma." While Eli Lilly (LLY) is expected to dominate the market share for these drugs, HIMS captures immense value by using these high-demand treatments as a "flywheel" to cross-sell its other health services. Long-term investors should view current entry points as a value opportunity, though they must be prepared for extreme volatility and potential geopolitical market risks.